Avivagen receives third OxC-beta order from UNAHCO
2017-05-26 09:42 ET - News Release
Mr. Kym Anthony reports
AVIVAGEN ANNOUNCES THIRD PURCHASE ORDER OF OXC-BETA LIVESTOCK FROM UNAHCO INC.
Avivagen Inc. has received a third purchase order from UNAHCO Inc. in the Philippines for OxC-beta Livestock 10 per cent premix at pricing in line with Avivagen's target. This purchase order is for 400 kilograms, representing more than 2.5 times the amount of the last purchase order of 150 kilograms, which was press released on April 6, 2017.
UNAHCO is the wholly owned feed and veterinary subsidiary of Unilab Inc., the biggest pharmaceutical company in the Philippines. UNAHCO provides a broad range of animal health care and nutrition products and programs to meet the requirements of both commercial and individual farmers in the Philippines as well as abroad. It is a leading producer of pig and poultry feed and has a distribution network that serves more than 3,000 outlets, supported by more than 100 field staff.
Avivagen intends to accelerate market access and the commercial uptake of its OxC-beta Livestock product. Avivagen operates in Canada with headquarters in Ottawa and is actively working with large, vertically integrated livestock producers and feed companies in the United States, Europe and Asia to drive regulatory approvals, market access and distribution agreements. Avivagen will press release any future firm purchase orders from new customers, as well as UNAHCO, to the extent those orders are material in their immediate, incremental contribution to Avivagen's financial performance.
About OxC-beta technology and OxC-beta Livestock
OxC-beta technology is derived from Avivagen discoveries about carotenoids, compounds that give certain fruits and vegetables their bright colours and is a non-antibiotic means of maintaining optimal health and growth. OxC-beta Livestock is a proprietary product shown to be effective and economic in replacing the antibiotics commonly added to livestock feeds. OxC-beta Livestock is currently registered and available for sale in the Philippines, Taiwan and Thailand.
Avivagen's product addresses one of the world's leading risks to human health: the rise of antibiotic-resistant bacteria, known as anti-microbial resistance. In order to preserve the effectiveness of antibiotics for human health, their use in the food chain as growth promoters for livestock animals must be eliminated. This use of antibiotics represents the single-largest and majority use of antibiotics globally. Government agencies, global health organizations, livestock producers, and end-market food companies and their customers are now reaching consensus on the need to raise livestock without the use of antibiotics. Consequently, the search is on for alternative products that will fill the gap to maintain health and productivity under modern production conditions.
Avivagen's OxC-beta Livestock product is safe and effective and could fulfill the global mandate to remove all in-feed antibiotics as growth promoters. Numerous international livestock trials with poultry and swine using OxC-beta Livestock have proved that the product performs as well as, and sometimes, in some aspects, better than in-feed antibiotics.
About Avivagen Inc.
Avivagen is headquartered in Ottawa, Canada, based in partnership facilities of the National Research Council of Canada and Charlottetown, PEI.
We seek Safe Harbor.